2021
866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors
Kuplast-Barr K, Kuplast-Barr K, Johnson M, Patel M, Yap T, Falchook G, LoRusso P, Abo R, Liu C, Manyak E, Cleary L, Bozon V, Parasuraman S, Keilhack H, McEachern K. 866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors. Journal For ImmunoTherapy Of Cancer 2021, 9: a907-a907. DOI: 10.1136/jitc-2021-sitc2021.866.Peer-Reviewed Original ResearchPreclinical modelsPatient tumor biopsiesTumor biopsiesAdaptive immunityCancer cellsHuman phase 1 studyTumor-specific immune memoryCD8 T cell infiltrationTumor microenvironmentPhase I clinical studyType IAdvanced solid tumorsPhase 1 studyT cell infiltrationGranzyme B expressionDurable tumor regressionAdaptive immune responsesInterferon-stimulated gene expressionImmune stimulatory effectsType I interferon responseCytosolic nucleic acidsType I interferonActivated T cellsNon-tumor tissuesI interferon response
2020
Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial.
Yap T, Gainor J, Burris H, Kummar S, Pachynski R, Callahan M, LoRusso P, Tykodi S, Gibney G, Falchook G, Rahma O, Seiwert T, Papadopoulos K, Mier J, Hashambhoy-Ramsay Y, Felitsky D, Lee D, McGrath L, Harvey C, Hooper E. Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial. Journal Of Clinical Oncology 2020, 38: 14-14. DOI: 10.1200/jco.2020.38.5_suppl.14.Peer-Reviewed Original ResearchCD4 T cellsCD4 T effector cellsT effector cellsT cellsRNA signatureRECIST responseClinical outcomesEffector cellsTumor biopsiesPre-treatment tumor biopsiesCD4 T cell populationBaseline tumor biopsiesPD-L1 TPSPD-1 inhibitorsAdvanced solid tumorsRetrospective subset analysisImmune cell infiltrationPotential predictive biomarkersT cell populationsPD-L1 IHCActivated T cellsBaseline tumorEfficacy outcomesPD-L1Combo therapy